Helicobacter投稿须知

期刊简介

《Helicobacter》是由Wiley-Blackwell Publishing Ltd出版社于1996年创办的英文国际期刊（ISSN: 1083-4389，E-ISSN: 1523-5378），该期刊长期致力于微生物学领域的创新研究，主要研究方向为医学-微生物学。作为SCIE收录期刊（JCR分区 Q1，中科院 2区），本刊采用OA未开放获取模式（OA占比0.0969...%），以发表微生物学领域等方向的原创性研究为核心（研究类文章占比75.29%%）。凭借严格的同行评审与高效编辑流程，期刊年载文量精选控制在85篇，确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库，为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Helicobacter审稿周期约为约2月。该刊近年未被列入国际预警名单，年发文量约85篇，录用竞争适中，主题需确保紧密契合医学前沿。投稿策略提示：避开学术会议旺季投稿以缩短周期，语言建议专业润色提升可读性。

医学大类学科
English 出版语言
否是否预警
SCIE 期刊收录
85 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊	综述期刊	大类学科	小类学科
否	否	医学 2区	MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 2区 3区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊	综述期刊	大类学科	小类学科
否	否	医学 2区	MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 2区 3区

JCR分区

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：GASTROENTEROLOGY & HEPATOLOGY	SCIE	Q1	29 / 143	80.1%
学科：MICROBIOLOGY	SCIE	Q2	44 / 161	73%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：GASTROENTEROLOGY & HEPATOLOGY	SCIE	Q2	36 / 143	75.17%
学科：MICROBIOLOGY	SCIE	Q2	54 / 161	66.77%

CiteScore

SJR

SNIP

CiteScore 排名

CiteScore：8.4

SJR：1.035

SNIP：1.249

学科类别	分区	排名	百分位
大类：Medicine 小类：Gastroenterology	Q1	19 / 167	88%
大类：Medicine 小类：Infectious Diseases	Q1	65 / 344	81%

期刊发文

Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy
Author: Han, Xinyuan; Yu, Xiqiu; Gao, Xiaojuan; Wang, Xiangyu; Tay, Chin Yen; Wei, Xiaolan; Lai, Bing; Marshall, Barry J.; Zhang, Xiuming; Chua, Eng Guan

Journal: HELICOBACTER. 2023; Vol. , Issue , pp. -. DOI: 10.1111/hel.12985
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
Author: Tian, Xue-li; Suo, Bao-jun; Zhang, Hua; Lu, Hao-ping; Li, Cai-ling; Zhang, Yu-xin; Ren, Xin-lu; Yao, Xing-yu; Zhou, Li-ya; Song, Zhi-qiang

Journal: HELICOBACTER. 2023; Vol. 28, Issue 1, pp. -. DOI: 10.1111/hel.12935
Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection
Author: Ji, Yan-Hong; Shi, Yan-Mei; Hei, Qian-Wen; Sun, Jin-Min; Yang, Xiao-Feng; Wu, Tao; Sun, Da-Li; Qi, Yu-Xing

Journal: HELICOBACTER. 2023; Vol. 28, Issue 1, pp. -. DOI: 10.1111/hel.12937
Discussion on the common controversies of Helicobacter pylori infection
Author: Yang, Hang; Mou, Yi; Hu, Bing

Journal: HELICOBACTER. 2023; Vol. 28, Issue 1, pp. -. DOI: 10.1111/hel.12938
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial
Author: Lu, Lifen; Wang, Yujing; Ye, Jun; Han, Yuehua; Lou, Guochun; Li, Yan; Yan, Huihui; Du, Qin

Journal: HELICOBACTER. 2023; Vol. 28, Issue 1, pp. -. DOI: 10.1111/hel.12940
Helicobacter pylori-positive chronic atrophic gastritis and cellular senescence
Author: Zheng, Shi-yu; Zhu, Lu; Wu, Lu-yi; Liu, Hui-rong; Ma, Xiao-peng; Li, Qi; Wu, Meng-die; Wang, Wen-jia; Li, Jing; Wu, Huan-gan

Journal: HELICOBACTER. 2023; Vol. 28, Issue 1, pp. -. DOI: 10.1111/hel.12944
Metabolic alterations in patients with Helicobacter pylori-related gastritis: The H. pylori-gut microbiota-metabolism axis in progression of the chronic inflammation in the gastric mucosa
Author: Zang, Hongmin; Wang, Jin; Wang, Huijie; Guo, Jiaxuan; Li, Yuchan; Zhao, Yinuo; Song, Jinzhong; Liu, Fengshuang; Liu, Xuzhao; Zhao, Yubin

Journal: HELICOBACTER. 2023; Vol. , Issue , pp. -. DOI: 10.1111/hel.12984
Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study
Author: Zhang, Wei; Gui, Qian; Chen, Jinnan; Yu, Dazhong; Su, Wenyu; Zhu, Changqing; Liang, Xiao; Lu, Hong

Journal: HELICOBACTER. 2023; Vol. 28, Issue 2, pp. -. DOI: 10.1111/hel.12946

Helicobacter

幽门螺杆菌

期刊简介

投稿提示

中科院分区

JCR分区

CiteScore

期刊发文

相关期刊

怎样选择期刊

投稿相关问题

投稿后咨询